GU Cancers 2023 | Phase III trial on neoadjuvant intravesical mitomycin C (MMC) treatment for bladder cancer

Massimo Lazzeri, MD, PhD, IRCCS Humanitas Research Hospital, Milan, Italy, provides an overview of the randomized Phase III clinical trial of neoadjuvant intravesical mitomycin C (MMC) treatment in patients with primary treatment-naïve non-muscle invasive bladder cancer (NMIBC). The primary endpoint was to evaluate the efficacy of MMC neoadjuvant treatment in reducing the recurrence rate calculated as the proportion of patients who achieve a complete response. The secondary clinical endpoint was the analysis of the rate of grade and stage progression to MIBC in case of recurrence and the correlation with specific biomarker. Patients were randomized to receive either MCC or the standard-of-care of transurethral resection (TUR) followed by adjuvant intravesical therapies with immunotherapy (BCG) and/or chemotherapy agents such as mitomycin C (MMC). This interview took place at the ASCO GU Cancers Symposium 2023 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.